|
 |
Faculty |
 |
Statement of Need |
 |
Activity Goal |
 |
Learning Objectives |
 |
Financial Support |
 |
Target Audience |
 |
Credit Information |
The Challenges of Bipolar Depression
neuroscienceCME Multimedia Snack
Premiere Date: Monday, November 3, 2014This activity offers CE credit for:
- Physicians (CME)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, November 3, 2015
Note: Credit Is No Longer Available
 | Charles B. Nemeroff, MD, PhD Professor and Chair Department of Psychiatry Mulva Clinic for the Neurosciences Director, Institute of Early Life Adversity Research Dell Medical School The University of Texas at Austin Austin, TX |
 | Joseph R. Calabrese, MD Bipolar Disorders Research Chair and Professor of Psychiatry Case Western Reserve University School of Medicine Director, Mood Disorders Program University Hospitals Case Medical Center Cleveland, OH |
Depression is the most common clinical presentation of bipolar disorder (BPD) and often challenges clinicians with a more complex approach to treatment than unipolar depression. Unlike the options available for the treatment of other psychiatric disorders, there are only three FDA-approved treatments for bipolar depression. In addition, according to the STAndards for BipoLar Excellence Project, regular monitoring for weight gain, hyperglycemia, extrapyramidal symptoms, and other side effects associated with treatment is needed for patients treated for BPD. Simultaneously managing both bipolar depression and treatment-related side effects is an ongoing challenge for clinicians.
In this neuroscienceCME Snack, the faculty will analyze and review treatment options for bipolar depression to offer clinicians the optimal, real-world context needed to combine the latest science with best practice to improve outcomes in patients with bipolar depression.
This educational activity centers on the CME Outfitters Make One Change statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change statement for this activity is:
Consistently evaluate symptoms, response, and treatment goals in concordance with patients with bipolar depression.
At the end of this CE activity, participants should be able to:
- Initiate an individualized treatment plan for bipolar depression that considers efficacy, side-effect profile, and metabolic impact.
This activity is supported by an educational grant from Sunovion Pharmaceuticals, Inc.
Physicians and other health care professionals who manage individuals with bipolar depression
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST925 (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Nemeroff has disclosed that he receives grants/research support from the National Institutes of Health (NIH). He serves as a consultant to Allergen, Inc.; Eli Lilly and Company; Lundbeck; Mitsubishi Tanabe Pharma Development America; Prismic Pharmaceuticals; SK Pharma; Roche; Shire Pharmaceuticals; Taisho Pharmaceutical Inc.; Takeda Pharmaceuticals North America, Inc.; and Xhale, Inc. He serves on the scientific advisory boards of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); CeNeRx BioPharma; National Alliance for Research on Schizophrenia and Depression (NARSAD); PharmaNeuroBoost; Xhale, Inc.; and Skyland Trail. He serves on the board of directors of the American Foundation for Suicide Prevention (AFSP); Anxiety Disorders Association of America (ADAA); GratitudeAmerica, Inc.; NovaDel Pharma, Inc. (2011); and Skyland Trail. He is a stockholder of AbbVie Inc,; Celgene Corporation; CeNeRx BioPharma; PharmaNeuroBoost; Reevax Pharmaceuticals LLC; Seattle Genetics, Inc.; and Xhale, Inc. His other financial income sources or equity of $10,000 or more include American Psychiatric Publishing; BioPharma; CeNeRx NovaDel Pharma, Inc.; Pharmaneuroboost; Revaax Pharmaceuticals LLC; and Xhale, Inc. He holds patents for the following: method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).
Dr. Calabrese has disclosed that he has received grant support from the Department of Defense; Health Resources and Services Administration; and National Institutes of Mental Health. He has received research support from Abbott Laboratories; AstraZeneca; Cephalon, Inc.; Cleveland Foundation; Eli Lilly and Company; GlaxoSmithKline; Lundbeck; NARSAD; and the Stanley Medical Research Institute. He serves as a consultant for Biomedical Development Corporation; Convergent Health Solutions, LLC; Dainippon Sumitomo Pharma Co., Ltd.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; Forest Laboratories, Inc.; GlaxoSmithKline; Health & Wellness Partners; Hoffmann-La Roche, Inc.; Lundbeck; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceuticals USA, Inc.
Tony Graham, MD (content/peer reviewer) has no disclosures to report.
Robert Kennedy (planning committee) has no disclosures to report.
Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.
Sandra Haas Binford, MAEd (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Sunovion Pharmaceuticals, Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
SN-061-110314-23
